Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma Exposure (Q39507721)

12 September 2017

Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma Exposure (English)

1 reference

12 September 2017

1 reference

17

Christine M Fandozzi

1 reference

12 September 2017

Michael T Rudd

1

1 reference

12 September 2017

John A McCauley

2

1 reference

12 September 2017

John W Butcher

3

1 reference

12 September 2017

Joseph J Romano

4

1 reference

12 September 2017

Charles J McIntyre

5

1 reference

12 September 2017

Kevin T Nguyen

6

1 reference

12 September 2017

Kevin F Gilbert

7

1 reference

12 September 2017

Kimberly J Bush

8

1 reference

12 September 2017

M Katharine Holloway

9

1 reference

12 September 2017

John Swestock

10

1 reference

12 September 2017

Bang-Lin Wan

11

1 reference

12 September 2017

Steven S Carroll

12

1 reference

12 September 2017

Jillian M DiMuzio

13

1 reference

12 September 2017

Donald J Graham

14

1 reference

12 September 2017

Steven W Ludmerer

15

1 reference

12 September 2017

Mark W Stahlhut

16

1 reference

12 September 2017

Nicole Trainor

18

1 reference

12 September 2017

David B Olsen

19

1 reference

12 September 2017

Joseph P Vacca

20

1 reference

12 September 2017

Nigel J Liverton

21

1 reference

12 September 2017

language of work or name

1 reference

12 January 2011

1 reference

ACS Medicinal Chemistry Letters

12 September 2017

1 reference

12 September 2017

2

1 reference

12 September 2017

3

1 reference

12 September 2017

207-212

1 reference

Advances in the development of macrocyclic inhibitors of hepatitis C virus NS3-4A protease

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017977

Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017977

MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017977

A review of HCV protease inhibitors

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017977

Macrocyclic inhibitors of HCV NS3 protease

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017977

Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017977

In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017977

Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017977

Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017977

Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017977

Unravelling hepatitis C virus replication from genome to function

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017977

Control of hepatitis C: a medicinal chemistry perspective

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017977

The management of side-effects during therapy for hepatitis C.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017977

Pathogenesis of hepatitis C-associated hepatocellular carcinoma

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017977

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017977

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017977

Side effects of therapy of hepatitis C and their management

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017977

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017977

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017977

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017977

In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017977

Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017977

Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017977

A time-resolved, internally quenched fluorescence assay to characterize inhibition of hepatitis C virus nonstructural protein 3-4A protease at low enzyme concentrations

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017977

Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335).

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017977

Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017977

Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017977

Hepatitis C and liver transplantation

21 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24900304

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Hepatitis C--global prevalence (update)

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24900304

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1021/ML1002426

1 reference

release_mxrne2la2va7fdclq5pldr4qzu

12 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mxrne2la2va7fdclq5pldr4qzu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

12 September 2017

PubMed publication ID

24900304

1 reference